The Presidential Transition Teams: A Reunion of “Pfizer Pfriends”?
When Hillary Clinton’s transition team was announced last week, much of the coverage focused (appropriately) on the health care experience of one co-chair, Neera Tanden. But another co-chair, former Michigan Governor Jennifer Granholm, also has an interesting history with the largest US pharma company – and, indirectly, with a member of Donald Trump’s transition team.
You may also be interested in...
Center for American Progress President Neera Tanden has actively advocated Clinton’s position on prescription drug price controls over the past year.
Biopharma industry is making some modest headway in quest to change the new US Medicare drug price process to treat drugs and biologics on equal footing. But eliminating the so-called ‘pill penalty’ would not on its own equalize the incentives for small molecule and large molecule R&D.
New drug pricing program under the Inflation Reduction Act could reduce the value of the 340B drug discount for safety net providers by as much as $1 billion in the first year, an analysis by the 340B Health association suggests.